We report here that expression of proteinase 3 (PR3), a serine protease, is down-regulated in the HL60/ADR multidrug resistant variant of the human myelogenous leukemia cell line HL-60, and that down-regulation of PR3 is associated with doxorubicin (DOX) resistance in these cells. To determine whether PR3 is involved in DOX-induced apoptosis in HL-60 cells, and whether its loss causes resistance to DOX, we inhibited PR3 expression by an anti-sense PR3 oligodeoxynucleotide and showed that inhibition of PR3 expression results in a significant reduction in DOX-induced DNA fragmentation and increased resistance to DOX-induced apoptosis. Our results revealed that PR3-mediated DOX-induced apoptosis in HL-60 cells is independent of the loss of mitochondrial membrane potential (DC m ) and activation of the caspase-8 and -9 pathways. Moreover, while PR3 is involved in the cleavage of caspase-3, PR3-mediated DOX-induced DNA fragmentation and apoptosis were not prevented by a specific inhibitor of caspase-3. These data suggest that activation of caspase-3 alone is not sufficient to trigger PR3-mediated DOX-induced apoptosis. Treatment with an anti-PR3 oligomer significantly decreased reactive oxygen species (ROS) generation in cells treated with low concentrations of DOX, revealing a role for PR3 in enhancing production of DOX-induced ROS. Moreover, DOX-induced apoptosis at 0.001 -0.01 mM was only inhibited in HL-60 cells pre-treated with the antioxidant N-acetyl-cysteine in the absence of anti-PR3, revealing that DOX-induced apoptosis in these cells is PR3-and ROS-dependent. Our results show that PR3 is involved in DOX-induced ROS-dependent apoptosis and that its loss is associated with resistance to DOX in HL-60 cells.
Introduction
Proteinase 3 (PR3), also referred to as myeloblastin, belongs to a family of neutrophil serine proteases including leukocyte elastase, cathepsin G, and the catalytically inactive azurocidin (Borregaard et al., 1993; Gullberg et al., 1995) . Previous studies have shown that PR3 degrades various extracellular matrix molecules such as type IV collagen, elastin, fibronectin, laminin, and vitronectin, indicating that it might be involved in tissue destruction and neutrophil migration (Rao et al., 1991; Chen et al., 1994) . This serine protease is involved in regulating the growth and differentiation of human leukemia cells (Bories et al., 1989) . PR3 is produced during myeloid differentiation at the promyelocytic stage (Sturrock et al., 1996) . However, its expression is not only limited to myeloid cells. Recently, studies have also reported the expression of this protein in other cell types (Mayet et al., 1997; Horman et al., 2000; Schwarting et al., 2000) .
PR3 is overexpressed in myeloid leukemia cells (Dengler et al., 1995) and colony-forming granulocytes/monocytes of patients with chronic myelogenous leukemia (Molldrem et al., 1997) . It is down-regulated during both normal myelopoiesis and the differentiation of human promyelocytic leukemia cell lines treated with different differentiation inducers (Bories et al., 1989; Labbaye et al., 1993; Zimber et al., 2000) . Recently, it was demonstrated that the PR3 gene is a granulocyte colony-stimulating factor-responsive gene conferring factor-independent growth to hematopoietic cells (Lutz et al., 2000) .
Multidrug resistance (MDR) is a major problem in the treatment of various human solid tumors and hematological malignancies (Safa, 1998) . There are several different mechanisms known to be involved in the development of MDR in human leukemia cell lines, including overexpression of the drug transporters Pglycoprotein (P-gp) or multidrug resistance-associated protein (MRP1), and alterations in apoptotic cell death mechanisms (Safa, 1998; Campos et al., 1993) . We have found that PR3 expression is significantly decreased in the drug resistant HL-60 subline, HL-60/ ADR, compared to the sensitive HL-60 cells. Therefore, in the present study, we investigated whether PR3 is involved in doxorubicin (DOX)-induced apoptosis and whether its loss increases resistance to apoptosis induced by this drug, and explored the pro-apoptotic role of PR3 in the apoptotic machinery and its possible role in increased reactive oxygen species (ROS) during DOX-induced apoptosis. Our results provide evidence that PR3 mediates DOX-induced apoptosis in HL-60 cells that is associated with activation of caspase-3 at 0.1 -1 mM DOX, and that at low concentrations of DOX, PR3-mediated apoptosis is enhanced through increased ROS generation.
Results

Drug resistance characteristics and analysis of PR3 and MRP1 expression in HL-60 and HL-60/ADR cells
The degree of resistance to (DOX), Vinblastine (VCR), and Vinblastin (VBL) in HL-60 and HL-60/ADR cells was measured by MTT cell survival assay. Our results show that the HL-60/ADR cells are about 122.5-14-and 8.5-fold more resistant to DOX, VCR and VBL, respectively, compared to their parental HL-60 cells (Table 1) . Consistent with these data, we have previously reported that HL-60/ADR cells overexpress MRP1, but not P-gp (Wu et al., 2001) .
The protein levels of PR3 in HL-60 and HL-60/ ADR cells were detected by two approaches: (a) immunoprecipitation of [ 35 S]methionine using the anti-PR3 monoclonal antibody MCPR3-2 (Sun et al., 1998) , and (b) flow cytometric detection of PR3 using the mouse anti-PR3 monoclonal antibody . Figure 1a shows that while a high level of PR3 was detected in HL-60 cells, its expression was down-regulated significantly in HL-60/ADR cells. Densitometric analysis of these data revealed that the level of PR3 protein synthesis in HL-60/ADR cells is 75% less than in HL-60 cells. Flow cytometric analysis also confirmed the immunoprecipitation results (Figure 1b and c) . Moreover, consistent with these results, RT -PCR analysis showed that the PR3 protein levels, in these cells were similar to their PR3 mRNA levels, which were down-regulated in HL-60/ADR cells compared to HL-60 cells, while their bactin mRNA levels were similar (Figure 1d ). To determine whether the down-regulation of PR3 in HL-60/ADR cells is controlled at the transcriptional level, nuclear run-on assay was performed. Figure 1e shows PR3 signals detected by hybridization of newly synthesized 32 P-UTP labeled nuclear run-on transcripts with a 360 bp PR3 cDNA fragment (lower bands) on slot blots in HL-60/ADR cells compared to HL-60 cells (panels 1 and 2, respectively).
Densitometric analysis of these results normalized to b-actin transcript levels (upper bands in Figure 1e ) revealed that the rate of transcription of the PR3 gene in HL-60/ADR cells is 25% less than in HL-60 cells. These results reveal that PR3 is partially downregulated at the transcriptional level in HL-60/ADR compared to HL-60 cells. However, as stated above, the extent of decreased PR3 expression at the protein level ( Figure 1a ) suggests that post-transcriptional events are also involved in down-regulating PR3 expression in HL-60/ADR cells.
Effects of inhibiting PR3 expression by anti-sense oligomer on DOX-induced cytotoxicity and apoptosis in HL-60 cells
To analyse whether decreased cellular PR3 expression contributes to the degree of drug resistance, we inhibited expression of PR3 using an 18-mer anti-sense oligomer (anti-PR3) containing a motif complementary to a PR3 cDNA sequence starting at position 95 downstream of the ATG initiation codon in HL-60 cells. This anti-PR3 oligomer has been previously shown to inhibit the expression of PR3 specifically in HL-60 cells (Bories et al., 1989) . First, the optimum concentration of anti-PR3 oligomer that inhibits PR3 expression was determined by treating sensitive HL-60 cells in the presence of various concentrations of anti-sense oligomer for 72 h. An 18-mer oligomer containing a nonspecific (NS) sequence with the exact base composition as anti-PR3 oligomer, but in random order, was used as a control. Following anti-PR3 or NS oligomer treatments, PR3 mRNA and protein levels were measured by RT -PCR ( Figure 2a ) and flow cytometry ( Figure  2b -d) , respectively. As shown in Figure 2a , treatment of HL-60 cells with 10 mM anti-PR3 oligomer abolished the PR3 mRNA levels compared to the untreated HL-60 or NS oligomer treated cells, while their mRNA levels for b-actin, used as internal controls, were comparable. Similar results were observed in flow cytometric analysis in which the PR3 protein levels in HL-60 cells treated with 10 mM anti-PR3 oligomer were undetectable compared to untreated cells or HL-60 cells treated with the nonsense oligomer ( Figure 2d , b and c, respectively). The anti-PR3 oligomer at 1, 2 and 5 mM and the NS oligomer at 1 -10 mM concentrations did not have any significant effect on the mRNA or protein levels of PR3 in HL-60 cells (data not shown). The effect of inhibiting PR3 expression by anti-PR3 oligomer on the sensitivity of HL-60 cells to DOX was assessed by treating these cells with increasing concentrations of DOX or VCR for 72 h in the absence or presence of 10 mM anti-PR3 or NS oligomers using the MTT cell survival analysis (Table 2 ). The results show that treating HL-60 cells in the presence of 10 mM anti-PR3 oligomer increased the IC 50 value of DOX, and as a result these cells expressed about 12-fold more resistance to this drug compared to untreated cells, while the presence of 10 mM NS oligomer did not cause any significant change in the degree of resistance (Table 2) . However, inhibition of PR3 expression had a negligible effect on the VCR sensitivity of HL-60 cells (data not shown). Moreover, we have found that adding 1 -10 mg/ml of PR3, as previously used in cultures of endothelial cells (Yang et al., 2001) , did not affect cell growth and apoptosis in HL-60 cells.
The effects of inhibiting PR3 on DNA fragmentation and apoptosis induced by DOX in HL-60 cells
To determine whether PR3 plays a role in apoptosis and whether its cellular loss causes resistance to DOX- (Figure 3) . Interestingly, as shown in Figure 3 , HL-60 cells treated with 10 mM anti-PR3 and 0.001 -0.1 mM DOX for 72 h expressed significantly less apoptosis than the controls (i.e., HL-60 cells or the cells treated with 10 mM NS in the absence or presence of 0.001 -0.1 mM DOX). When HL-60 cells were pre-treated with 10 mM anti-PR3 or NS oligomers for 72 h, then exposed to growth media containing these oligomers plus 0.01 mM DOX and 0.1 mM DOX, respectively, for 72 h, similar results were observed.
In the second approach, we measured the rate of apoptotic cell death in HL-60 cells treated as described above by flow cytometry using the TUNEL assay. Our results show 1.9-, 3.3-, and 4.17-fold increases in DOXinduced apoptosis compared to the control untreated HL-60 cells when the cells were treated with 0.001, 0.01, and 0.1 mM DOX, respectively (Figure 4a -d) . Similarly, 1.9-, 2.2-and 3.7-fold increases in DOXinduced apoptosis were observed in the presence of 10 mM NS oligomer and 0.001, 0.01 and 0.1 mM DOX, respectively, compared to untreated cells, respectively (Figure 4e -h ). However, in the presence of 10 mM anti-PR3 oligomer, only 9.35, 10.83 and 12.53% apoptotic cells due to treatment with 0.001, 0.01, and 0.1 mM DOX, respectively, were detected compared to number of apoptotic cells in the untreated control cells (Figure  4i -l) . These results reveal that the inhibition of PR3 by its anti-sense oligomer causes resistance to apoptosis induced by DOX in HL-60 cells, hence PR3 is involved in DOX-induced apoptosis in these cells. However, 1 mM DOX treatment for 72 h killed greater than 90% of HL-60 cells, as well as cells treated with either anti-PR3 or NS oligomers using the above approaches, suggesting that at this dose of the drug, other factors should also be involved in DOX-induced apoptosis. Interestingly, as shown in Figures 3 and 4 , 10 mM anti-PR3 or NS oligomer in the absence of DOX did not affect the level of intrinsic apoptosis in these cells.
To quantitatively determine the levels of DOXinduced apoptosis in untreated or DOX-treated HL-60 cells in the absence of NS or anti-PR3 oligomer, we performed DAPI staining and annexin V binding assays. In the DAPI assay, apoptotic cells are identified by condensation and fragmentation of their nuclei. The data shown in Figure 5a -j clearly show treatment with 0.01 and 0.1 mM DOX induced significantly more apoptosis in HL-60 cells treated in the absence or presence of NS oligo than in the presence of anti-PR3 oligo as visualized by DAPI staining of HL-60 cells. Consistent with the cell death ELISA assay and TUNEL assay, quantitation of apoptosis assessed by DAPI staining revealed that treating HL-60 cells with 0.01 and 0.1 mM DOX for 72 h in the presence of 10 mM anti-PR3 oligomer induced about fivefold less apoptosis than the cells treated with the same concentrations of DOX and 10 mM NS oligomer (Figure 5e ). At 1 mM DOX, about 90 -95% of cells died in the absence or presence on 10 mM NS or anti-PR3 oligomer (data not shown).
Early in the apoptotic process, phospholipid asymmetry in the plasma membrane is disrupted, leading to the exposure of phosphatidylserine on the outer leaflet of the plasma membrane. Annexin V is an anti- Figure 4 Analysis of the effects of down-regulation of PR3 on the apoptotic cell death in HL-60 cells by TUNEL assay. The sensitive HL-60 cells were incubated with 10 mM NS or anti-PR3 oligomers in the absence (7) or presence of 0.001 mM DOX, 0.01 mM DOX or 0.1 mM DOX for 72 h at 378C as described in Materials and methods. DNA fragmentation due to apoptotic cell death was measured by flow cytometry using the TUNEL assay as described in Materials and methods. Fold increase in apoptosis in each treatment group compared to their respective controls are shown. The results are representative of three independent experiments Figure 5 Detection of DOX-induced apoptosis and effects of anti-PR3 oligomer in HL-60 cells by DAPI staining. DAPI staining of untreated HL-60 cells (a), the cells treated with 0.01 mM DOX (b) and 0.1 mM DOX (c); HL-60 cells treated with 10 mM NS oligomer (d), the cells treated with 10 mM NS oligomer plus 0.01 mM DOX (e), and the cells treated with 10 mM NS oligomer plus 0.1 mM DOX (f); HL-60 cells treated with 10 mM anti-PR3 oligomer (g), the cells treated with 10 mM anti-PR3 oligomer plus 0.01 mM DOX (h) and the cells treated with 10 mM anti-PR3 oligomer plus 0.1 mM DOX (i). Quantitation of apoptosis induced by 0.01 mM and 0.1 mM DOX treatment in the absence or presence of 10 mM NS or anti-PR3 oligomer in HL-60 cells for 72 h by DAPI staining (j) as described in Materials and methods coagulant protein that preferentially binds to negatively charged phospholipids and can be used to identify apoptosis. We used fluorescein-conjugated annexin V (FITC annexin V) as described in Materials and methods to determine apoptotic cell death in cultures of HL-60 cells treated with various concentrations of DOX in the absence or presence of 10 mM NS or anti-PR3 oligomer. Date presented in Figure 6 revealed that treating HL-60 cells with 0.001 and 0.1 mM DOX for 72 h in the presence of 10 mM anti-PR3 oligomer induced significantly less apoptosis than the cells treated with the same concentrations of DOX and 10 mM NS oligomer ( Figure 6 ). Consistent with DAPI staining results, DOX at 1 mM killed about 90 -95% of cells in the absence or presence of 10 mM NS or anti-PR3 oligomer (data not shown).
To elucidate the molecular mechanisms of the involvement of PR3 in DOX-induced apoptosis in HL-60 cells, we first determined whether PR3 induces apoptosis through the mitochondrion-initiated pathway. As shown in Figure 7a and b, treatment of HL-60 cells with 0.1 mM DOX either alone or in the presence of anti-PR3 or NS oligomer for 72 h, had no significant effect on DC m . It has been shown that As 2 O 3 at low concentrations induces apoptosis in sensitive and drug resistant HL-60 cells (Perkins et al., 2000) . therefore, as control experiments, we treated HL-60 cells with 3 mM As 2 O 3 for 72 h and determined mitochondrial DC m . As 2 O 3 induced a decrease in DC m in HL-60 cells, as well as in HL-60 cells treated with NS or anti-PR3 oligomers (Figure 7c ), indicating that PR3 is not involved in As 2 O 3 -induced apoptosis
To investigate whether PR3-mediated DOX-induced apoptosis is associated with activation of caspases-3, -8 and -9, we performed Western blot analysis using the HL-60 cells untreated or treated with 0.01, 0.1 and 1 mM DOX in the presence of 10 mM NS or anti-PR3 oligomers for 72 h and antibodies to caspases-3, -8 and -9. The antibodies used recognize both the procaspases and the cleaved activated forms of these enzymes. Western blot analysis of caspase-3 showed that this caspase was cleaved to a 17 kDa fragment in HL-60 cells during apoptosis induced by 0.1 and 1 mM DOX treatment for 72 h in the absence or presence of 10 mM NS oligomer (Figure 8a) . Interestingly, caspase-3 in HL-60 cells was cleaved only when the cells were treated with 1 mM DOX in the presence of 10 mM anti-PR3 oligomer (Figure 8b and c) . Consequently, 10 times more DOX is required to cleave caspase-3 when the cells are treated with anti-PR3 oligomer. Interestingly, Western blotting of HL-60 cells treated with 0.01, 0.1 and 1 mM DOX for 72 h in the absence or presence 10 mM NS or anti-PR3 oligomer using a caspase-8 or caspase-9 antibody showed that DOX induced degradation of neither of these caspases (Figure 8b and c). These results revealed that cleavage of caspase-3 in proteinase-3-mediated DOX-induced apoptosis is independent of the caspase-8 and -9 pathways, and that proteinase-3 is involved in activating caspase-3.
To investigate whether caspase-3 cleavage and activation alone is sufficient to cause DOX-induced apoptosis in HL-60 cells and whether there is a functional relationship between PR3 and caspase-3 in mediating DOX-induced apoptosis, we pre-incubated the cells with 100 mM of the caspase-3 inhibitor Ac-DEVD-CHO for 3 h and continued to treat them with 0.1 mM DOX in the absence or presence of 10 mM NS or anti-sense oligomers for 72 h. The results presented in Figure 9a and b show that Ac-DEVD-CHO treatment did not significantly inhibit DOX-induced apoptosis as determined by cell death ELISA and annexin V-binding assays. These results suggest that activation of caspase-3 may only be one of the events for apoptosis.
To determine whether inhibition of PR3 affects Bcl-2 and Bcl-x L levels, HL-60 cells were treated with 0.01, 0.1 and 1 mM DOX plus or minus 10 mg/ml NS or anti-PR3 and compared to control cells. Western blot analysis revealed no significant changes in the levels of these proteins when the cells were treated with 0.01 and 0.1 mM DOX. However, Bcl-x L was not detected in cells treated with 1 mM DOX plus or minus the oligomers, and Bcl-2 was decreased in these samples (Figure 10a and b) . These results suggest that the lack of Bcl-x L and degradation of Bcl-2 contribute to DOXinduced apoptosis at 1 mM DOX. Our data also showed that Sp1 expression slightly increased in HL-60 cells treated with anti-PR3. Moreover, the levels of expression of the anti-apoptotic heat shock protein 70 (HSP 70) as well as apoptosis-induced factor (AIF) were not changed in cells treated with 0.01 -1 mM DOX. Similarly, HL-60 cells treated with anti-PR3 for 72 h did not express MRP1 or P-glycoprotein, compared to the untreated or NS oligomer treated cells, as revealed by immunoprecipitation of 35 S-labeled cells (data not shown), indicating that increased These results suggest that DOX-induced apoptosis in HL-60 cells is independent of the loss of mitochondrial DC m and caspase-8 and -9 pathways, and that cleavage of caspase-3 plays a role in PR3-mediated DOXinduced apoptosis at 0.1 and 1 mM DOX. However, PR3-mediated DOX-induced DNA fragmentation and apoptosis at 0.001 and 0.01 mM DOX was not associated with cleavage of caspase-3, suggesting the involvement of a mechanism(s) independent of the caspase-3, -8, and -9 pathways. In addition to DNA intercalating properties, anthracyclines including daunorubicin (DNR) and DOX have other mechanisms of action including induction of lipid peroxidation and generation of ROS. Moreover, it is known that increased ROS are likely to act as signaling intermediates that are involved in the signal transduction pathways of apoptosis (Liu et al., 2000; Rodriguez et al., 1996; Yang et al., 1996) . Therefore, we measured increased production of ROS during DOX-induced apoptosis and determined whether PR3 has a role in increased ROS production by various concentrations of DOX. Data shown in Figure 11a clearly demonstrate that treating HL-60 cells with 0.01 -1 mM DOX in the presence or absence of 10 mM NS oligomer for 72 h significantly increased ROS generation. However, treatment with the same concentrations of DOX and 10 mM anti-PR3 oligomer very significantly decreased ROS generation, revealing a role for PR3 in enhancing production of DOX-induced ROS. As a negative control, 0.01 -1 mM VCR was used instead of DOX, but no enhancement of ROS was detected (data not shown). To determine whether DOX induces apoptosis through a PR3-and ROS-dependent pathway, HL-60 cells were treated with 10 mM of the antioxidant Nacetylcysteine and 0.01 or 0.1 mM DOX in the absence or presence 10 mM NS or anti-PR3 oligomer for 72 h and relative apoptosis was determined by annexin V binding assay. Data presented in Figure 11b demon- 
Discussion
In this study, we show that expression of PR3, a serine protease, is down-regulated by transcriptional and post-transcriptional mechanisms in drug resistant HL-60/ADR cells. To determine whether down-regulation of PR3 in HL-60 cells causes resistance to apoptosis induced by DOX and provide data revealing that PR3 is involved in DOX-induced apoptosis, we used an anti-sense oligodeoxynucleotide to PR3 in HL-60 cells. Our data for the first time revealed that inhibition of PR3 expression results in the development of resistance to DOX-induced apoptosis in HL-60 cells. Therefore, down-regulation of PR3 in HL-60/ADR cells is a novel mechanism that these cells have acquired during the development of the DOX resistance phenotype. Several reports (Yang et al., , 2001 Taekema-Roelvink et al., 1988) have previously shown that adding exogenous PR3 to cultures of endothelial cells internalizes and causes apoptosis in these cells. Moreover, primed neutrophils from patients with primary small vessel vasculitis express PR3 on the cell surface and undergo apoptosis more readily than controls (Harper et al., 2001) , but the molecular mechanisms of PR3-induced apoptosis in endothelial cells and neutrophils remain to be found. However, our data revealed that adding PR3 to cultures of HL-60 did not affect the intrinsic level of apoptosis in these cells. Our results support the previous finding that epithelial cells also do not have the capacity to internalize PR3 and do not die by -12) for 72 h were processed. Note that only 1 mM DOX in HL-60 cells treated with 10 mM anti-PR3 oligomers caused cleavage of caspase-3 to 17 kDa active fragment, while the HL-60 cells in the absence or presence of NS oligomer, 0.1 mM DOX was able to cause cleavage of this caspase Figure 9 Effects of the caspase-3 inhibitor on PR3-mediated DOX-induced apoptosis. HL-60 cells were pre-treated with 100 mM Ac-DEVD-CHO 3 h before treating them with 0.1 mM DOX in the presence of NS or anti-PR3 oligomer for 72 h and apoptosis was determined by (a) cell death ELISA assay and (b) annexin V-binding assay as described in Materials and methods apoptosis when they are exposed to exogenous PR3 (Yang et al., 2001) . It is well documented that caspases play a central role in the execution of apoptosis and the two most well-studied pathways of caspase activation include the mitochondrion-initiated pathway and the cell surface death receptors pathway (Strasser et al., 2000) . In the mitochondrial pathway, cytochrome c and other apoptosis-induced factors are released from the intramembrane space to the cytosol (Liu et al., 1996; Susin et al., 1996) . Once released, cytochrome c binds to apoptotic proteinase activating factor-1 (Apaf-1) and this complex, along with adenine nucleotides, promotes procaspase-9 autoactivation (Li et al., 1998) , which in turn activates caspase-3 and caspase-7 (Wolf and Green, 1999). In the death receptor-mediated apoptosis pathways (Fas/Fas ligand interaction and cell death), caspase-8 is a key caspase that can activate the downstream caspases including caspase-3. Active caspase-8 also causes the release of mitochondrial cytochrome c (Li et al., 1998; Luo et al., 1998) thereby linking the two pathways. After activation, both caspase-8 and caspase-9 activate caspase-3, which in turn cleaves and activates other caspases and many cellular proteins including fodrin, protein kinase C d (PKC d), poly (ADP-ribose) polymerase (PARP), gelsolin, DNA fragmentation factor-45 (DFF45) (Decker et al., 2000; Kunstle et al., 1997; Nicholson and Thornberry, 1997; Wolf and Green, 1999) , and Sp1 (Piedrafita and Pfahl, 1997). While proteolysis of these and other caspase substrates induces the hallmark of apoptotic cell death, recent reports have also provided evidence for caspaseindependent apoptosis (Borner and Monney, 1999; Johnson, 2000) . For example, serine proteases have been reported to play a crucial role in the early cleavage of chromatin into 50 -300 kb pieces before they are digested to nucleosome-sized fragments by caspase activated DNAse (CAD), also termed DNA fragmentation factor (DFF) (Hughes et al., 1997) . Similarly, another serine protease, AP24, becomes activated during apoptosis, and agents that inhibit activation of this protease protect cells from tumor necrosis factor-a (TNF-a) and UV-induced apoptosis (Wright et al., 1997) . Interestingly, caspase activation by non-caspase proteinases also represents another mechanism of activation (Liu et al., 2000) . Granzyme B, an aspartate-specific serine proteinase, can activate To determine whether the increased ROS generated by DOX treatment and mediated through PR3 caused apoptosis, HL-60 cells were treated with or without 10 mM of the antioxidant Nacetylcysteine in the absence or presence of 0.001, 0.01, or 0.1 mM DOX, plus or minus 10 mg/ml NS or anti-PR3 oligos for 72 h. Apoptotic cell death was measured by flow cytometry using fluorescein-conjugated annexin V as described in Materials and methods. Fold increase in apoptosis in each treatment group compared to their respective conrols are shown. The results are the average of three independent experiments several caspases and vigorously induces apoptosis (Stennicke and Salvesen, 1999) . Several other proteinases including the cysteine proteinase, calpain, apoptotic serine proteinase p24 and cathepsin D have also been shown to be involved in apoptosis (Squier et al., 1994; Wright et al., 1994; Deiss et al., 1996; Hirsch et al., 1998; Nakagawa and Yuan, 2000) . Our results demonstrated that at 0.1 mM DOX, PR3-mediated DOX-induced apoptosis in HL-60 cells was independent of the caspase-8 and -9 pathways, but was associated with the cleavage of caspase-3 in HL-60 cells. At 1 mM, DOX-induced apoptosis was associated with caspase-3 cleavage and downregulation of Bcl-2, Bcl-x L . However, inhibition of caspase-3 by its specific inhibitor did not inhibit DOX-induced apoptosis significantly, suggesting that cleavage and activation of caspase-3 alone is not sufficient to commit apoptotic cell death. Consistent with these results, Wright et al. (1997) have demonstrated that activation of caspase-3 alone is not sufficient for apoptosis induced by TNF-a or UV light, and Gamen et al. (2000) found that although DOX induced activation of several caspases in the human T-cell leukemia Jurkat cell line, cotreatment of these cells with inhibitors of these caspases prevented many morphological features of apoptosis but not cell death. Previously, it has been shown that DOX-induced apoptosis occurs by a Fasindependent pathway (Eischen et al., 1997) and that in some cellular systems, apoptosis induced by DOX causes disruption of the inner mitochondrial membrane potential (DC m ) that precedes apoptosis (Decaudin et al., 1997) . However, our results suggest that DOXinduced apoptosis in HL-60 is independent of the loss of mitochondrial membrane potential (DC m ). Indeed, recent reports show that in HL-60 cells, collapse of DC m is not part of the central apoptotic machinery, and is not required for the release of cytochrome c and AIF and caspase activation (Finucane et al., 1999; Li et al., 2000) . Our data resemble those reported for etoposide-induced apoptosis (Hishita et al., 2001) in P39 cells, a myelodysplastic syndrome cell line, in which no change in DC m was detected and caspase-3 was activated by a cytochrome c-independent, but lysosomal enzyme-dependent, pathway.
Our results documented that at low concentrations of DOX, PR-3-mediated DOX-induced apoptosis is associated with increased production of reactive oxygen species and therefore provides evidence suggesting a role for redox state in regulating apoptotic cell death induced by this drug in HL-60 cells. There is accumulating evidence that ROS may serve as signaling molecules in inducing apoptotic cell death by various death stimuli, but how ROS may regulate apoptosis is unknown (Rodriguez et al., 1996; Kunstle et al., 1997; Bauer, 2000; Liu et al., 2000; Herrera et al., 2001) . A major source of ROS is the mitochondria, in which cytochrome c release activates caspases that further increase ROS production. However, it is known that cellular sources of ROS are numerous including mitochondrial respiratory chain enzymes, NADPH oxidase, the cytochrome P-450 enzyme system, lipoxygenases, cyclo-oxygenases, xanthine oxidase, and nitric oxide synthase (Jiang et al., 1999; Bauer and Bauer, 1999; Tammariello et al., 2000) . Moreover, NADPH dehydrogenase plays an important role in generating ROS during DOX treatment (Wong et al., 2000) . However, the role of PR3 in increased ROS production, as well as the action of ROS production, and the role of ROS in DOX-induced apoptosis, remain to be addressed.
Evidence suggest that decreased PR3/myeloblastin expression is associated with growth arrest and differentiation in HL-60 cells treated constantly with differentiating agents such as 1,25-(OH) 2 D 3 (Bories et al., 1989; Labbaye et al., 1993; Chen et al., 1994) . However, it was pointed out previously that in the HL-60 system, the appearance of phenotypic markers for differentiation (such as CD14 antigen and non-specific esterase) occurs much earlier than the disappearance of PR3 (Rao et al., 1998) , suggesting that downregulation of PR3 might be essential but not sufficient by itself for differentiation. This is in agreement with our results in which decreased expression of PR3 by anti-sense oligomer treatment for 72 h did not result in growth arrest or withdrawal of HL-60 cells from cell cycle (Wu et al., unpublished results) . Moreover, we have demonstrated that the drug resistant HL-60/ADR cells expressing a very low level of PR3 grow much faster than sensitive HL-60 cells expressing a high level of PR3 (Kraveka and Safa, unpublished data). Furthermore, it was reported previously that a significant decrease in c-myc mRNA levels was observed in differentiated HL-60 cells (Shen-Ong et al., 1987; Holt et al., 1988) , indicating that there might be other proteins associated with differentiation. Taken together, these results strongly suggest that downregulation of PR3 expression per se might not be enough to trigger growth arrest and differentiation, and that a combination of several altered factors such as PR3 and c-myc may be interrelated. Indeed, recent data suggest that functional interactions between nuclear bile acid signaling pathways, protein kinase C, and nuclear receptors for retinoic acid and vitamin D 3 are involved in down-regulating proteinase 3 and inducing differentiation in human leukemic cells (Zimber et al., 2000) . Our results clearly demonstrate that proteinase 3 is involved in DOX-induced apoptosis. However, little is known about the biological targets of PR3 which may be involved in apoptosis. Previous data (Rao et al., 1998) , as well as our own results (Ogretmen and Safa, unpublished results) , show that the addition of PR3 in vitro cleaves the Sp1 transcription factor, and that a 30 kDa fragment of Sp1 degraded by PR3 was recognized by an antibody of C-terminal region of these protein, suggesting that this transcription factor is a substrate of PR3. However, our in vivo results presented in this report using an anti-PR3 oligomer revealed only a small increase in the expression of Sp1, suggesting that this transcription factor is not a good substrate for PR3. Recently, other proteins including the heat shock proteins (HSPs) 27 and 28 (Spector et al., 1995; Horman et al., 2000) , interleukin-6 (Bank et al., 1999) and AP1 transcription factor (Ogretmen and Safa, unpublished results) were shown to be degraded by PR3 in vitro. These HSPs have an anti-apoptotic function and are also involved in cellular differentiation (Arrigo, 1998; Bruey et al., 2000; Morano and Thiele, 1999) . However, our in vivo results showed that the expression level of HSP 27 is not increased in HL-60 cells treated with anti-PR3 oligomer. Consequently, the findings described in this report, that PR3 is involved in inducing apoptosis in HL-60 cells and that downregulation of PR3 by an anti-sense oligomer results in the development of resistance to DOX by inhibiting apoptosis, provide a novel function for this protein. Moreover, for the first time we showed that downregulation of PR3 in HL-60/ADR cells during the development of the drug resistance phenotype is associated with drug resistance mechanism. These results indicate that PR3 is a new target for DOX-induced apoptosis and should be used to identify or develop other agents which may use this protein to mediate apoptosis. Moreover, lack of expression of PR3 in refractory acute myelocytic leukemia may serve as a negative prognostic indicator.
Materials and methods
Cell lines and culture conditions
The human acute myeloid leukemia (AML) cell line HL-60 and its MRP-mediated variant HL-60/ADR (McGrath et al., 1989) were originally obtained from Dr Melvin S Center (Division of Biology, Kansas State University, Manhattan, KS, USA). Cells were maintained in RPMI-1640 medium with 10% fetal calf serum (FCS) and 100 ng/ml each of penicillin and streptomycin (Life Technologies, Grand Island, NY, USA) at 378C in 5% CO 2 . HL-60/ADR cells were grown in the presence of 1 mg/ml DOX, which was removed from the media 1 week before each assay. VCR and VBL were obtained from Eli Lilly and Co. (Indianapolis, IN, USA) and DOX was purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Cell survival assay
MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay was performed as previously described (Fleming et al., 1992) . Briefly, 5610 4 cells were plated in 100 ml of the growth medium in the presence or absence of increasing concentrations of chemotherapeutic drugs into 96-well plates and cultured at 378C in 5% CO 2 for 72 h. The cells were then incubated with 25 ml MTT (5 mg/ml) at 378C for 4 h. After dissolving the crystals in 0.04 N HCl in isopropanol, plates were read in a microplate reader (Dynatech Lab. Inc., Chantilly, VA, USA) at 570 nm. The concentration of drug that inhibited cell survival by 50% (IC 50 ) was determined from cell survival plots. To determine whether adding exogenous PR3 affect cell survival, we treated the cells with 1 -10 mg/ml PR3 (Yang et al., 2001) for 72 h and cell survival was determined by MTT and cell death ELISA assays. PR3 was obtained from Athens Research and Technology, Inc. (Athens, GA, USA). The specific activity of PR3 used in these experiments was determined by Athens Research and Technology, Inc., according to Hoidal et al. (1994) using t-butyloxy carbonyl p-nitrophenylester (Boc-AlaOPhNO 2 ) as a substrate. The specific activity of the PR3 used was 16 mm of p-nitrophenol/mg PR3/min at room temperature.
Immunoprecipitations
The expression level of PR3 was determined by immunoprecipitation analysis as we described previously (Ogretmen and Safa, 1997) . In short, the cells (about 5610 5 ) were incubated in 2 ml methionine-free growth media containing 50 mCi [ 35 S]methionine for 18 h at 378C. Following phosphate buffered saline (PBS) washes, the cells were resuspended in lysis buffer (142.5 mM KCl, 5 mM MgCl 2 , 10 mM HEPES, 1 mM EGTA, 0.2% IGEPAL, 2 mM PMSF and 1 mg/ml leupeptin) and frozen at -808C. Following 35 S-methionine labeling, equal TCA counts of the lysates (1610 6 c.p.m.) were used for immunoprecipitation. After the lysates were precleared with 50 ml protein G-agarose (Life Technologies, Rockville, MD, USA), they were incubated with 20 mg of the mouse anti-PR3 monoclonal antibody MCPR3-2 (Sun et al., 1998) (obtained from Dr Ulrich Specks, Mayo Clinic and Foundation, Rochester, MN, USA) for 1 h at 48C. The immunocomplexes were then precipitated using protein Gagarose for 1 h at 48C. The agarose beads were washed two times with washing buffer containing 50 mM Tris-Base, 150 mM NaCl, 1 mM EDTA, 1% deoxycholate, 1% T-X100, 0.1% sodium dodecyl sulfate (SDS), 1 mM PMSF and two times with 50 mM TBS to remove nonspecific binding. The immunocomplexes were then resuspended in equal volumes of SDS-sample buffer and analysed by SDS -PAGE followed by fluorography as described (Ogretmen and Safa, 1997) . The immunoprecipitated proteins were detected by autoradiography. PR3 was quantitated by densitometric analysis using Photoshop version 4 software.
Western blot analysis
Western blot analysis was performed as we described elsewhere (Ogretmen and Safa, 1997) . The Bcl-2 mouse monoclonal antibody Bcl-2 (100), and the Bcl-x S-L rabbit polyclonal antibody Bcl-x S-L (S-18) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), and used at 1:1000 dilutions (v/v or w/v). The mouse monoclonal anti-b-actin clone AC-74 used at 1:2000 (w/v) dilution was purchased from Sigma (St. Louis, MO, USA). For detecting caspases and their activation, rabbit anti-capase-3 polyclonal antibody and the rabbit anti-caspase-9 polyclonal antibody were purchased from BD Pharmingen (San Diego, CA, USA), and the anti-caspase-8 monoclonal antibody 1C12 was purchased from Cell Signaling Technology (Beverly, MA, USA). These antibodies were used at 1:1000 dilutions (v/v). In short, 5610 5 cells or 50 mg protein/lane were separated by 5 -15% SDS -PAGE containing 6.5 M urea, blotted onto a PDVF Immobilon membrane, then the protein levels were detected using 1:1000 (v/v or w/v) dilutions of the antibodies and the peroxidase-conjugated secondary anti-mouse, antigoat, or anti-rabbit antibody (1:2500 v/v) (Amersham, Arlington Heights, IL, USA). The proteins were visualized using the ECL protein detection kit (Amersham, Arlington Heights, IL, USA) as described by the manufacturer. The membranes were then exposed to Kodak X-Omat film for various times. Equal loading was confirmed by probing the same blots using the mouse monoclonal anti-b-actin antibody (Sigma, St. Louis, MO, USA). All immunoblots were repeated between 2 -3 times.
RNA isolation and RT -PCR
PR3 mRNA levels were analysed by PT -PCR. In short, total RNA from HL-60 and HL-60/ADR cells were isolated either as we previously described (Ogretmen and Safa, 1995) or using Tri Reagent TR-118 (Molecular Research Center, Cincinnati, OH, USA) as described by the manufacturer. One mg of total RNA was used in reverse transcription reactions with M-MLV reverse transcriptase and oligo (dT) 15 primer (Promega, Madison, WI, USA) as described by the manufacturer. The resulting total cDNA was then used as the template in PCR to measure the PR3 mRNA levels. The primers of PCR were as follows: PR3 forward 5'-TTCTGCGGAGGCACCTTGAT-3' (106 -125); PR3 reverse 5'-ATTGAGCTCCTGCAGGACCT-3' (446 -465); b-actin forward 5'-CAGAGCAAGAGAGGCATCCT-3' (216 -235); b-actin reverse 5'-TTGAAGGTCTCAAACATGAT-3' (405 -424). The reactions were performed at 948C for denaturation, 588C for annealing and 728C for extension for 30 cycles. The b-actin mRNA levels were used as internal controls. The amplified fragments were separated on 1.5% agarose gels and visualized by ethidium bromide staining.
Nuclear run-on transcription assay
Nuclear run-on analysis was performed as previously described (Ogretmen et al., 1998) . Briefly, nuclei from HL-60, HL-60/ADR cells were isolated and stored in 100 ml of freezing buffer (50 mM Tris-HCl, pH 8.3, 40% glycerol, 5 mM MgCl 2 and 0.1 mM EDTA). For analysis, nuclei were thawed and incubated with 100 ml of reaction buffer containing 10 mM Tris-HCl, pH 8.0, 5 mM MgCl 2 , 300 mM KCl, 0.5 mM each of ATP, CTP and GTP and 150 -200 mCi of [a-32 P]UTP at 308C for 30 min. Reactions were stopped by DNase I treatment (100 units) at 308C for 20 min. Following deproteinization by proteinase K (25 mg/ml) at 428C for 30 min, the labeled transcripts were extracted by phenol/ chloroform (49:1) and then precipitated using ethanol and sodium acetate. Equal counts of TCA-precipitated labeled transcripts were used for hybridizations of slot blots containing 0.4 mg 360 bp human PR3 and 1.8 kb human b-actin (CloneTech, Palo Alto, CA, USA) cDNA fragments. Hybridizations were performed at 458C for 72 -96 h and then filters were washed at 578C with 26SSC -1% SDS and 0.16SSC -1% SDS for 1 -2 h as we previously described (Ogretmen et al., 1998) . Bands were visualized by autoradiography at -808C for 7 -10 days, and quantitated by densitometry using Photoshop version 4 software. The levels of labeled PR3 transcripts in HL-60 and HL-60/ADR cells were determined after subtracting the background levels and normalized to their labeled b-actin transcripts.
Flow cytometric analysis of PR3 expression
HL-60 or HL-60/ADR cells ( 5610 6 ) were centrifuged and fixed with buffered formaldehyde acetone (Slaper-Cortenbach et al., 1988) for 4 s at RT. The reaction was stopped by adding excess PBS. The cells were then spun down and resuspended in 200 ml PBS. Twenty ml of anti-PR3 monoclonal antibody PR3 4A5 (Wieslab, Lund, Sweden) were added to the cell suspension and incubated for 30 min on ice. After washing, FITC-conjugated anti-mouse IgG (Fc specific, Sigma, St. Louis, MO, USA) was added in a 1:32 dilution for another 30 min on ice. Following rinsing, the samples were analysed with flow cytometric quantitation using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA). The data were quantitated using the Cell Quest program.
Anti-sense oligodeoxynucleotides and treatment of HL-60 cells
The phosphorothioated 18-mer antisense PR3 (5'-CTGGGGTATGTCCCGCAG-3') (Bories, 1989) and nonspecific (NS) 5'-CGGCCGTAGTGTTCGGAC-3') oligodeoxynucleotides were synthesized at GIBCO -BRL (Rockville, MD, USA). The lyophilized oligomers were resuspended in dH 2 O at a final concentration of 1 mM. 1610 7 cells were treated with or without antisense PR3 or NS oligomers for 72 h at 378C in 12 well plates, and mRNA and protein levels of PR3 were measured by RT -PCR, immunoprecipitation and flow cytometry, respectively, as described above. The effects of antisense PR3 on HL-60 cell survival, DNA fragmentation, and apoptosis were assessed by incubating the cells in the presence or absence of 10 mM anti-sense PR3 or NS oligomers with or without increasing concentrations of DOX for 72 h at 378C using MTT assay (described above), Cell Death ELISA and TUNEL assays, DAPI staining and annexin V binding assay (described below).
Detection of DNA fragmentation due to apoptosis DNA fragmentation due to apoptotic cell death in HL-60 cells, incubated with or without antisense PR3 or NS oligomers in the presence or absence of DOX concentrations for 72 h at 378C, was measured by terminal increasing deoxynucleotidyltransferase (TdT) dUTP nick end labeling (TUNEL) assay and Cell Death ELISA. For TUNEL assay, the Apo-Direct Kit (Pharmingen, San Diego, CA, USA) was used as described by the manufacturer. In short, 5610 6 HL-60 cells were fixed in 1% paraformaldehyde for 15 min on ice and then kept in 70% ethanol for 12 -18 h at -208C. After washing, the cells were incubated with TdT and fluorescein conjugated anti-dUTP antibody for 60 min at 378C. The extent of DNA fragmentation was then analysed by the Cell Quest program using a FACSCalibur flow cytometry (Becton Dickinson, San Jose, CA, USA). Apoptosis was analysed by the quandrant statistics on the propidium iodide (PI) negative, FITC positive cells. For the cell death ELISA, the Cell Death Detection ELISA kit (Roche, Indianapolis, IN, USA) was used as described by the manufacturer. In short, 5610 4 HL-60 cells were suspended in 200 ml lysis buffer and incubated for 30 min at RT. After centrifugation, 20 ml supernatant were transferred to the streptavidin-coated microtiter plate (MTP) and then 80 ml of immunoreagent was added to each well followed by incubation and shaking for 2 h at RT. After rinsing, ABTS substate was added, and the color development for photometric analysis was measured at 405 nm against ABTS solution as a blank by a MRX ELISA reader (Dynatech Lab Inc., Chantilly, VA, USA).
Detection of apoptosis by DAPI staining
DAPI staining was performed on unreated and DOX-treated cells in the absence or presence on NS or anti-PR3 oligos as described previously . In brief, prior to staining, the cells were fixed with 4% paraformaldehyde for 30 min at room temperature. After washing with PBS by centrifugation at 650 g, DAPI was added to the fixed cells for 30 min, after which they were examined by confocal fluorescence microscopy. Apoptotic cells were indentified by condensation and fragmentation of nuclei. A minimum of 400 cells were counted for each treatment and the percentage of apoptotic cells was calculated as the ratio of apoptotic cells to total cells counted 6100. The DAPI staining experiments were performed in duplicate.
Annexin V binding assay for detection of apoptotic cells
Following treatment with DOX, DOX plus NS or DOX plus anti-PR3, in the absence or presence of 10 mM NAC, the cells were then used for determining the translocation of phosphatidylserine to the outer surface of the plasma membrane during apoptosis using the human phospholipid binding protein, annexin V, conjugated with fluorescein (Molecular Probes, Eugene, OR, USA) by flow cytometry as described by the manufacturer.
Effect of caspase-3 inhibitor on HL-60 cells
To determine whether caspase-3 is involved in DOX-induced apoptosis mediated by PR3, the caspase-3 inhibitor Ac-AspGlu-Val-Asp-CHO (Ac-DEVD-CHO) was purchased from CalBiochem (San Diego, CA, USA), dissolved in dimethylsulfoxide (DMSO; Sigma, St. Louis, MO, USA) and used. The final concentration of DMSO was 0.1%. HL-60 cells (1610 4 ) were incubated in growth media in the presence or absence of 100 mM of this caspase inhibitor for 3 h at 378C, then the cells were treated with or without 10 mg/ml NS or anti-PR3 oligos for 72 h in the absence or presence of 0.1 mM DOX, and finally processed for the Cell Death ELISA and annexin V-binding assays for detection of apoptosis as described below.
Cytofluorimetric analysis of mitochondrial DC m
Variations of the mitochondrial transmembrane potential DC m during HL-60 cell apoptosis were studied using 3,3'-dihexyloxacarbocyanine ([DiOC 6 (3)]; Molecular Probes Inc., Eugene, OR, USA). This dye accumulates in the mitochondrial matrix under the influence of the DC m (Chen, 1988) . HL-60 cells were incubated with or without anti-sense PR3 or NS oligomers in the presence or absence of increasing DOX concentrations or 3 mM arsenic trioxide (As 2 O 3 ) (Sigma, St. Louis, MO, USA). As 2 O 3 was dissolved in 1.65 M sodium hydroxide (NaOH) to make a stock solution of 1 M and serially diluted in PBS. After 24 h incubation, 5610 5 cells were incubated in 200 ml of PBS containing 0.1 mM of DiOC 6 (3) for 30 min. DiOC 6 (3) membrane potential-related fluorescence was recorded using FL1 PMT by FACSCalibur flow cytometry.
Analysis of reactive oxygen species (ROS)
Levels of intracellular ROS were measured using dichlorodihydrofluorescein diacetate (DCFH-DA; Molecular Probes, Inc., Eugene, OR, USA). HL-60 cells (5610 5 ) were untreated or treated with 0.01 -1 mM DOX with or without 10 mM NS or anti-PR3 in culture media for 72 h. Subsequently, the cells were incubated for 15 min at 378C with 5 mM dichlorodihydrofluorescein diacetate (DCFH-DA) and analysed by FACSCalibur flow cytometry as described previously (Amarante-Mendes et al., 1998) . The analysis of ROS was accomplished in duplicate experiments. To determine whether the increased ROS generated by DOX treatment and mediated through PR3 caused apoptosis, HL-60 cells were treated without or with 10 mM of the antioxidant NAC in the absence or presence of 0.01 or 0.1 mM DOX plus or minus 10 mM NS or anti-PR3 oligos for 72 h. Apoptosis was then measured by annexin V binding assay using flow cytometry as described above.
